Company Encyclopedia
View More
name
Alnylam Pharma
ALNY.US
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.
1.946 T
ALNY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking8/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE32.73%A
    • Profit Margin1.36%C
    • Gross Margin83.98%A
  • Growth ScoreA
    • Revenue YoY53.24%A
    • Net Profit YoY113.11%A
    • Total Assets YoY15.38%A
    • Net Assets YoY622.92%A
  • Cash ScoreA
    • Cash Flow Margin7368.46%A
    • OCF YoY53.24%A
  • Operating ScoreB
    • Turnover0.71B
  • Debt ScoreE
    • Gearing Ratio95.18%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation?

    Alnylam Pharmaceuticals (ALNY) stock has surged 12% in the past month and nearly doubled over the past year, raising questions about its valuation. The stock is priced at $473, slightly below Wall Street's target of $489, suggesting a modest 3.2% undervaluation. However, a DCF model indicates a 21% undervaluation with a fair value near $601. The growth is driven by AMVUTTRA's uptake and RNAi therapies' market expansion. Risks include pricing pressure and high R&D costs. Investors are advised to consider other innovative healthcare stocks.

    Simplywall·
    US
    ALNY
    -1.68%
    Simplywall·
    US
    ALNY
    -1.68%

    Alnylam Pharmaceuticals Appoints Stuart Arbuckle to Board as Mike Bonney and Carolyn Bertozzi Step Down

    Alnylam Pharmaceuticals Inc. announced changes to its Board of Directors. Mike Bonney and Carolyn Bertozzi will step down on December 2, 2025. Stuart Arbuckle will join as an independent director on January 5, 2026.

    Reuters·
    US
    ALNY
    -1.68%
    Reuters·
    US
    ALNY
    -1.68%

    The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Raised Sales Guidance for Vutrisiran

    Alnylam Pharmaceuticals raised its sales guidance for vutrisiran due to stronger-than-expected demand, boosting its leadership in gene-silencing therapies. The updated 2025 revenue guidance reflects confidence in the ATTR-CM opportunity but highlights reliance on the TTR franchise. Investors should consider high payer and reimbursement risks. Alnylam projects $7 billion revenue and $1.9 billion earnings by 2028, requiring 41.8% yearly growth. Fair value estimates vary, indicating differing perspectives on the company's future worth.

    Simplywall·
    US
    ALNY
    -1.68%
    Simplywall·
    US
    ALNY
    -1.68%

    A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance

    Alnylam Pharmaceuticals raised its sales guidance after vutrisiran therapy exceeded expectations, boosting investor confidence. The stock surged 90.5% over the past year, with a total shareholder return of 75.4%. Analysts suggest the stock is undervalued with a fair value of $480.17, despite trading at a premium price-to-sales ratio. Potential risks include pricing pressures and reliance on a single franchise. Investors are encouraged to explore further investment opportunities.

    Simplywall·
    US
    ALNY
    -1.68%
    Simplywall·
    US
    ALNY
    -1.68%

    American Century Companies Inc. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

    American Century Companies Inc. increased its holdings in Alnylam Pharmaceuticals by 1.9% in Q2, owning 1,793,846 shares worth $584.96 million. Other hedge funds also adjusted their stakes. Analysts have given Alnylam a consensus 'Moderate Buy' rating with a target price of $482.17. The stock opened at $436.38, with a market cap of $57.65 billion. CEO Yvonne Greenstreet and EVP Jeffrey V. Poulton sold shares recently.

    Market Beat·
    US
    ALNY
    -1.68%
    Market Beat·
    US
    ALNY
    -1.68%
    © 2025 Longbridge｜Disclaimer